Results 211 to 220 of about 58,502 (304)

Single‐center experience of the Crohn's disease exclusion diet in the United States: A retrospective study

Nutrition in Clinical Practice, EarlyView.
Abstract Background The Crohn's Disease Exclusion Diet (CDED) offers a dietary means of inducing and maintaining remission for patients with Crohn's disease (CD). Descriptions of efficacy have emerged primarily from Israel, Europe, and Canada. Here, we offer real‐world experience, from a tertiary care center in the United States. Methods We conducted a
Mayah Greenfield, Caroline Salozzo, Wenya Chen, Jennifer Strople, Jeffrey Brown, Joseph Runde   +5 more
wiley   +1 more source

Transperineal Ultrasound-Guided Endoscopic Sinusotomy for Recurrent Perianal Sinus in Crohn Disease. [PDF]

ACG Case Rep J
Pal P, Mateen MA, Gupta R, Tandan M, Reddy DN.   +4 more
europepmc   +1 more source

Mycobacterium avium ssp. paratuberculosis detection in animals, food, water and other sources or vehicles of human exposure: A scoping review of the existing evidence [PDF]

McEwen, S A, Rajic, A, Staerk, K D C, Waddell, L A   +3 more
core   +1 more source

The Association of Pregnancy and Scurvy in Indigenous Women and Their Children From the Late Holocene in California (USA)

International Journal of Osteoarchaeology, EarlyView.
ABSTRACT Limited evidence of nutritional deficiencies has been identified in bioarchaeological studies of Native California populations, although isotopic and ethnohistoric research provides evidence of regional, seasonal, and cultural variability in food shortages.
Alyson Caine, Christopher Canzonieri, Eric J. Bartelink, Andrew Galvan   +3 more
wiley   +1 more source

Stomal calprotectin as a biomarker for assessing Crohn disease activity in patients with stomas. [PDF]

Intern Med J
Abeyratne K, Harb M, Bensted K, Ghaly S, Connor SJ, Andrews JM, Lynch KD.   +6 more
europepmc   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source

Successful treatment of therapy-resistant metastatic Crohn's desiase with infliximab [PDF]

, 2004
CASTIGLIONE, FABIANA, COZZOLINO A, INSABATO, LUIGI, LEMBO, GIUSEPPE, PESCE, GIUSEPPE, RISPO A   +5 more
core   +1 more source

Appendiceal Crohn's Disease Manifesting as Appendiceal Malignancy: A Case Report and Review of the Literature

The Kaohsiung Journal of Medical Sciences, EarlyView.
Ming‐Jung Meng, Tai‐Di Chen, Puo‐Hsien Le, Chia‐Jung Kuo   +3 more
wiley   +1 more source

Effectiveness and Safety of Setmelanotide in a Patient With a Heterozygous PCSK1 Deficiency

Obesity, EarlyView.
ABSTRACT Setmelanotide, a melanocortin 4 receptor (MC4R) agonist, is a promising pharmacological treatment option for people with rare monogenic obesity conditions affecting the leptin‐melanocortin signaling pathway, including proprotein convertase subtilisin/kexin type 1 (PCSK1) gene mutations.
Ellina Lytvyak, Arshdeep Rattol, Eduardo Grunvald   +2 more
wiley   +1 more source

First Reported Successful Use of Infliximab Maintenance Therapy for Dual Treatment of Crohn Disease and Idiopathic Retroperitoneal Fibrosis. [PDF]

ACG Case Rep J
Isaac-Coss G, Post Z, Kakarla M, Johnsky L, Sakuraba A, Miller I, Shriram JM, Frasca J.   +7 more
europepmc   +1 more source